Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenetic and metabolic reprogramming by HDAC inhibition targets NRF2-active tumors

ABSTRACT: Epigenetic and metabolic reprogramming by HDAC inhibition targets NRF2-active tumors

PROVIDER: PRJNA911718 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Epigenetic and metabolic reprogramming by HDAC inhibition targets NRF2-active tumors [RNA-Seq]

Project description:To investigate the NRF2-specific cytotoxic effects of HDAC inhibition, we assessed gene expression in the context of control and NRF2-overexpressing mouse LUAD cells upon HDAC inhibition.

2023-03-30 | GSE220837 | GEO

Epigenetic and metabolic reprogramming by HDAC inhibition targets NRF2-active tumors [CUT&Tag]

Project description:To investigate the NRF2-specific cytotoxic effects of HDAC inhibition, we assessed genomic distribution of histone acetylation modifications and readers in the context of control and NRF2-overexpressing mouse LUAD cells upon HDAC inhibition.

2023-03-30 | GSE220832 | GEO

Epigenetic and metabolic reprogramming by HDAC inhibition targets NRF2-active tumors [CUT&Tag]

Project description:Epigenetic and metabolic reprogramming by HDAC inhibition targets NRF2-active tumors [CUT&Tag]

| PRJNA911637 | ENA

Epigenetic and metabolic reprogramming by HDAC inhibition targets NRF2-active tumors [CRISPR Screen]

Project description:Epigenetic and metabolic reprogramming by HDAC inhibition targets NRF2-active tumors [CRISPR Screen]

| PRJNA911659 | ENA

Epigenetic and metabolic reprogramming by HDAC inhibition targets NRF2-active tumors [RNA-Seq]

Project description:Epigenetic and metabolic reprogramming by HDAC inhibition targets NRF2-active tumors [RNA-Seq]

| PRJNA911727 | ENA

Epigenetic and metabolic reprogramming by HDAC inhibition targets NRF2-active tumors [CRISPR Screen]

Project description:To identify NRF2-specific dependencies in chromatin regulation, we performed a focused genetic screen mouse LUAD cell lines with or without knock-out of KEAP1.

2023-03-30 | GSE220831 | GEO

Epigenetic and metabolic reprogramming by HDAC inhibition targets NRF2-active tumors

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-03-30 | GSE220839 | GEO

Functional analysis of the cytoprotective transcription factor Nrf2 in keratinocytes: Identification of Nrf2-regulated miRNAs

Project description:Nrf2-regulated mRNAs are known; however, no Nrf2-regulated miRs have been identified miR microarray analysis from total RNA samples was performed to test which miRs are regulated by Nrf2 Total RNA from skin of mice with constitutively active Nrf2 (CMV-caNrf2), dominant-negative Nrf2 (dnNrf2), and correcponding control littermates (K5Cre(wt) for CMV-caNrf2 and wt for dnNrf2)

2015-01-01 | E-GEOD-52454 | biostudies-arrayexpress

Metabolic reprogramming by histone deacetylase inhibition preferentially targets NRF2-activated tumors.

Project description:The interplay between metabolism and chromatin signaling is implicated in cancer progression. However, whether and how metabolic reprogramming in tumors generates chromatin vulnerabilities remain unclear. Lung adenocarcinoma (LUAD) tumors frequently harbor aberrant activation of the NRF2 antioxidant pathway, which drives aggressive and chemo-resistant disease. Using a chromatin-focused CRISPR screen, we report that NRF2 activation sensitizes LUAD cells to genetic and chemical inhibition of class I histone deacetylases (HDACs). This association is observed across cultured cells, mouse models, and patient-derived xenografts. Integrative epigenomic, transcriptomic, and metabolomic analysis demonstrates that HDAC inhibition causes widespread redistribution of H4ac and its reader protein, which transcriptionally downregulates metabolic enzymes. This results in reduced flux into amino acid metabolism and de novo nucleotide synthesis pathways that are preferentially required for the survival of NRF2-active cancer cells. Together, our findings suggest NRF2 activation as a potential biomarker for effective repurposing of HDAC inhibitors to treat solid tumors.

| S-EPMC10853943 | biostudies-literature

Nrf2 transcript alterations

Project description:WGS and RNA-seq data for Nrf2 study

| EGAS00001001740 | EGA